Apolipoprotein A-I (apoA-I) activators encompass a diverse group of chemical compounds that enhance the functional activity of apoA-I through various mechanisms related to its central role in lipid transport and cardiovascular health. Compounds like 4-Phenylbutyrate and Probucol act to stabilize apoA-I, with the former promoting proper protein folding and the latter preserving lipid binding functionality by preventing oxidation. Retinoid X receptor (RXR) agonists such as Bexarotene and liver X receptor (LXR) agonists like GW3965 and T0901317 elevate the expression of the ATP-binding cassette transporter A1 (ABCA1), crucial for lipidating apoA-I, thereby enhancing its capacity to efflux cholesterol. Inhibitors such as Sulfosuccinimidyl oleate (SSO) indirectly support apoA-I by reducing competition for lipid binding, while Glyburide influences lipid metabolism, potentially affecting apoA-I's lipid interactions. Synthetic peptide mimetics D-4F and HDL mimetic peptide L-4F, designed to emulate apoA-I's function, directly contribute to the enhancement of cholesterol efflux and protection against lipid oxidation, complementing the natural protein's atheroprotective functions.
Additionally, novel agents like RVX-208 have been identified toincrease apoA-I production, while the Apolipoprotein A-I Milano (ApoA-IM) variant offers insight into enhanced protective functionalities of apoA-I, suggesting potential pathways for activation. Rosiglitazone, a PPARγ agonist, is involved in the upregulation of ABCA1 expression, thus facilitating apoA-I's role in cholesterol efflux. These activators ultimately collaborate to amplify apoA-I's key role in reverse cholesterol transport-a critical process in reducing the risk of atherosclerosis and associated cardiovascular diseases. Each activator, by targeting specific aspects of the biochemical pathways that apoA-I is involved in, ensures that the protein's ability to mobilize and transport lipids, particularly cholesterol, is optimized, reinforcing its essential function in maintaining lipid homeostasis and vascular health.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sodium phenylbutyrate | 1716-12-7 | sc-200652 sc-200652A sc-200652B sc-200652C sc-200652D | 1 g 10 g 100 g 1 kg 10 kg | $77.00 $166.00 $622.00 $5004.00 $32783.00 | 43 | |
A chemical chaperone that can enhance the stability of apoA-I by promoting proper folding, which is crucial for its role in reverse cholesterol transport. | ||||||
Probucol | 23288-49-5 | sc-203666 sc-203666A | 100 mg 1 g | $79.00 $166.00 | 5 | |
An antioxidant that may preserve the functionality of apoA-I by preventing the oxidation of lipids with which apoA-I interacts, thus maintaining efficient lipid binding. | ||||||
Bexarotene | 153559-49-0 | sc-217753 sc-217753A | 10 mg 100 mg | $55.00 $250.00 | 6 | |
A retinoid X receptor (RXR) agonist that can upregulate ABCA1 expression, leading to increased lipidation of apoA-I and enhanced cholesterol efflux. | ||||||
RVX 208 | 1044870-39-4 | sc-472700 | 10 mg | $340.00 | ||
A small molecule that increases apoA-I production and enhances HDL cholesterol efflux capacity, indirectly enhancing apoA-I function. | ||||||
Glyburide (Glibenclamide) | 10238-21-8 | sc-200982 sc-200982A sc-200982D sc-200982B sc-200982C | 1 g 5 g 25 g 100 g 500 g | $46.00 $61.00 $117.00 $173.00 $530.00 | 36 | |
An ATP-sensitive potassium channel inhibitor that may indirectly enhance apoA-I activity by modulating cellular metabolism and influencing lipid profiles. | ||||||
GW3965 | 405911-09-3 | sc-490151 sc-490151A sc-490151B | 10 mg 50 mg 1 g | $260.00 $872.00 $1637.00 | ||
A liver X receptor (LXR) agonist that may increase apoA-I synthesis and HDL formation by upregulating ABCA1, a key regulator of cholesterol efflux involving apoA-I. | ||||||
T 0901317 | 293754-55-9 | sc-202824 sc-202824A | 10 mg 50 mg | $89.00 $224.00 | 5 | |
Another LXR agonist with a similar function to GW3965, potentially increasing apoA-I levels and its associated lipid transport capacity. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
A peroxisome proliferator-activated receptor gamma (PPARγ) agonist that may upregulate ABCA1 expression, leading to enhanced apoA-I mediated cholesterol efflux. | ||||||